Supportive Oncodermatology Update: LUT014 Gel Shows Significant Efficacy in Treating Acneiform Rash Associated with Use of Anti-EGFR Cancer Therapies
Lutris Pharma’s LUT014 gel showed significant efficacy in treating acneiform rash associated with the use of epidermal growth factor receptor (EGFR) inhibitor therapy, according to Phase 2 data presented at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025 in Barcelona, Spain.